137 related articles for article (PubMed ID: 19747326)
1. Facial acne during topical pimecrolimus therapy for vitiligo.
Li JC; Xu AE
Clin Exp Dermatol; 2009 Oct; 34(7):e489-90. PubMed ID: 19747326
[No Abstract] [Full Text] [Related]
2. Focal acne during topical tacrolimus therapy for vitiligo.
Bakos L; Bakos RM
Arch Dermatol; 2007 Sep; 143(9):1223-4. PubMed ID: 17875902
[No Abstract] [Full Text] [Related]
3. Pimecrolimus: a new choice in the treatment of vitiligo?
Eryilmaz A; Seçkin D; Baba M
J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1347-8. PubMed ID: 19309422
[No Abstract] [Full Text] [Related]
4. Facial flush reaction after alcohol ingestion during topical pimecrolimus and tacrolimus treatment.
Stinco G; Piccirillo F; Sallustio M; Patrone P
Dermatology; 2009; 218(1):71-2. PubMed ID: 18832812
[No Abstract] [Full Text] [Related]
5. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream.
Gorman CR; White SW
Arch Dermatol; 2005 Sep; 141(9):1168. PubMed ID: 16172323
[No Abstract] [Full Text] [Related]
6. Rosaceiform eruption to pimecrolimus.
El Sayed F; Ammoury A; Dhaybi R; Bazex J
J Am Acad Dermatol; 2006 Mar; 54(3):548-50. PubMed ID: 16488319
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
Dawid M; Veensalu M; Grassberger M; Wolff K
J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
[TBL] [Abstract][Full Text] [Related]
8. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
[TBL] [Abstract][Full Text] [Related]
9. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo.
Hui-Lan Y; Xiao-Yan H; Jian-Yong F; Zong-Rong L
Pediatr Dermatol; 2009; 26(3):354-6. PubMed ID: 19706108
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo.
Mayoral FA; Vega JM; Stavisky H; McCormick CL; Parneix-Spake A
J Drugs Dermatol; 2007 May; 6(5):517-21. PubMed ID: 17679186
[TBL] [Abstract][Full Text] [Related]
11. Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream.
Bilaç DB; Ermertcan AT; Sahin MT; Oztürkcan S
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):72-3. PubMed ID: 18355205
[No Abstract] [Full Text] [Related]
12. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
Hartmann A; Bröcker EB; Hamm H
J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
[TBL] [Abstract][Full Text] [Related]
13. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
Coskun B; Saral Y; Turgut D
Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818
[TBL] [Abstract][Full Text] [Related]
14. Topical pimecrolimus: a new horizon for vitiligo treatment?
Sendur N; Karaman G; Saniç N; Savk E
J Dermatolog Treat; 2006; 17(6):338-42. PubMed ID: 17853306
[TBL] [Abstract][Full Text] [Related]
15. Pimecrolimus cream in repigmentation of vitiligo.
Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
[TBL] [Abstract][Full Text] [Related]
16. [Acne and contact dermatitis].
Romaguera C; Mascaró JM; Grimalt F
Med Cutan Ibero Lat Am; 1982; 10(4):245-50. PubMed ID: 6222231
[TBL] [Abstract][Full Text] [Related]
17. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
[TBL] [Abstract][Full Text] [Related]
18. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
Chu CY
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
[TBL] [Abstract][Full Text] [Related]
19. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
van der Laan JR
Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1816; author reply 1817. PubMed ID: 16121669
[No Abstract] [Full Text] [Related]
20. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
Ormerod AD
Br J Dermatol; 2005 Oct; 153(4):701-5. PubMed ID: 16181449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
